Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
The compound was never approved as a pharmaceutical treatment for obesity because the Phase 2 clinical trial results, while showing safety and modest efficacy, did not meet the threshold for drug registration
Following administration in animal models: BPC-157 demonstrates rapid systemic distribution within 15-30 minutes with unusual oral bioavailability TB-500 shows tissue-specific accumulation with preferential uptake in injured areas GHK-Cu exhibits copper-mediated transport and gene-modulating tissue binding KPV utilizes PepT1 transporter-mediated uptake with enhanced delivery to inflamed tissues Combined formulation provides immediate, sustained, and targeted bioactivity across multiple mechanisms Distribution studies suggest that injury sites and inflamed tissues tend to concentrate multiple components through different mechanisms BPC-157 through injury-site targeting, TB-500 through actin-rich repair zones, GHK-Cu through copper-dependent pathways, and KPV through upregulated PepT1 in inflammation, potentially enhancing local therapeutic effects
Osteocyte: Derived from osteoblasts, located within the bone matrix, responsible for sensing bone stress, regulating bone metabolism, and maintaining calcium and phosphorus balance
Do I need previous experience
For doses at the 2.5mg/ml concentration, a 1ml (100-unit) insulin syringe works for all doses up to 2.4mg
US$ 22.52
US$ 23.90
US$ 23.68
US$ 22.23
US$ 23.83
US$ 21.03
US$ 27.60
US$ 29.74
